
compared with those receiving ASA alone at 12 and 24 months
(OR, 0.59; 95% CI, 0.46-0.76). This effect was not seen in
those patients undergoing prosthetic bypass grafts, where
patency was identical in those receiving ASA and coumarin.
Twice as many bleeding complications were observed in patients receiving coumarin as in those receiving ASA.
Despite the Ô¨Ånd